{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:32:28Z","timestamp":1761539548497},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNCI J Natl Cancer Inst"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1093\/jnci\/djw255","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T11:06:01Z","timestamp":1476270361000},"page":"djw255","source":"Crossref","is-referenced-by-count":22,"title":["Recommendations for Clinical Trial Development in Follicular Lymphoma"],"prefix":"10.1093","volume":"109","author":[{"given":"Kami","family":"Maddocks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Baizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,12,31]]},"reference":[{"issue":"7","key":"2016123117301574000_109.3.djw255.1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin\u2019s lymphomas: Distributions of the major subtypes differ by geographic location. Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"182","author":"Anderson","year":"1998","journal-title":"Ann Oncol."},{"key":"2016123117301574000_109.3.djw255.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3990"},{"key":"2016123117301574000_109.3.djw255.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"2016123117301574000_109.3.djw255.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3991"},{"issue":"7","key":"2016123117301574000_109.3.djw255.5","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","article-title":"Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d-Etude des Lymphomes Folliculaires 86 Trial","volume":"16","author":"Solal-Celigny","year":"1998","journal-title":"J Clin Oncol."},{"key":"2016123117301574000_109.3.djw255.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00169-2"},{"key":"2016123117301574000_109.3.djw255.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"2016123117301574000_109.3.djw255.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491514"},{"key":"2016123117301574000_109.3.djw255.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"2016123117301574000_109.3.djw255.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.086"},{"key":"2016123117301574000_109.3.djw255.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112303"},{"key":"2016123117301574000_109.3.djw255.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.5853"},{"key":"2016123117301574000_109.3.djw255.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"2016123117301574000_109.3.djw255.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"2016123117301574000_109.3.djw255.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"2016123117301574000_109.3.djw255.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"2016123117301574000_109.3.djw255.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"2016123117301574000_109.3.djw255.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0866"},{"key":"2016123117301574000_109.3.djw255.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"2016123117301574000_109.3.djw255.20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"2016123117301574000_109.3.djw255.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"2016123117301574000_109.3.djw255.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.4101"},{"key":"2016123117301574000_109.3.djw255.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1120"},{"key":"2016123117301574000_109.3.djw255.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.8327"},{"key":"2016123117301574000_109.3.djw255.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"2016123117301574000_109.3.djw255.26","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"2016123117301574000_109.3.djw255.27","doi-asserted-by":"crossref","unstructured":"Martin P Jung S Johnson J , . CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. Paper presented at the 11th International Conference on Malignant Lymphoma; June 2013; Lugano, Switzerland.","DOI":"10.1200\/jco.2014.32.15_suppl.8521"},{"key":"2016123117301574000_109.3.djw255.28","doi-asserted-by":"crossref","unstructured":"Trotman J Luminari S Boussetta S , . Prognostic value of PET-CT after frontline therapy in follicular lymphoma: A pooled analysis of central review in three multicenter studies. Paper presented at the American Society of Clinical Oncology Annual Meeting; June 2014; Chicago, IL.","DOI":"10.1016\/S2352-3026(14)70008-0"},{"key":"2016123117301574000_109.3.djw255.29","doi-asserted-by":"crossref","unstructured":"Wong-Sefidan I Byrtek M Zhou X , . PET compared with CT as a prognosticator after rituximab induction therapy in follicular lymphoma: Report from the Nation Lymphocare Study. Paper presented at the 55th annual meeting of the American Society for Hematology; December 2013; New Orleans, LA.","DOI":"10.1182\/blood.V122.21.4245.4245"},{"key":"2016123117301574000_109.3.djw255.30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.0934"},{"key":"2016123117301574000_109.3.djw255.31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt562"},{"key":"2016123117301574000_109.3.djw255.32","doi-asserted-by":"crossref","unstructured":"Casulo C Byrtek M Dawson K , . Early relapse of follicular lymphoma after R-CHOP uniquely defines patients at high risk for death: An analysis from the National Lymphocare Study. Paper presented at the 55th annual meeting of the American Society for Hematology; December 2013; New Orleans, LA.","DOI":"10.1182\/blood.V122.21.510.510"},{"key":"2016123117301574000_109.3.djw255.33","doi-asserted-by":"crossref","unstructured":"Maurer MJ Ghesquieres H Ansell S , . Event-free survival at 12 months (EFS12) from diagnosis is a robust endpoint for disease-related survival in patients with follicular lymphoma in the immunochemotherapy era. Paper presented at the 56th annual meeting of the American Society for Hematology; December 2014; San Francisco, CA.","DOI":"10.1182\/blood.V124.21.1664.1664"},{"key":"2016123117301574000_109.3.djw255.34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12754"},{"key":"2016123117301574000_109.3.djw255.35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3806"},{"key":"2016123117301574000_109.3.djw255.36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.3.1149"},{"key":"2016123117301574000_109.3.djw255.37","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.050930"},{"key":"2016123117301574000_109.3.djw255.38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63186"},{"key":"2016123117301574000_109.3.djw255.39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571786"},{"key":"2016123117301574000_109.3.djw255.40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330795"},{"key":"2016123117301574000_109.3.djw255.41","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2856"},{"key":"2016123117301574000_109.3.djw255.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"2016123117301574000_109.3.djw255.43","doi-asserted-by":"crossref","unstructured":"Fowler N Advani R Sharman J , . The Bruton\u2019s tyrosine kinase inhibitor Ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. Paper presented at the 54th annual meeting of the American Society for Hematology; December 2012; Atlanta, GA.","DOI":"10.3109\/10428194.2013.777837"},{"key":"2016123117301574000_109.3.djw255.44","doi-asserted-by":"crossref","unstructured":"Bartlett NL LaPlant BR Qi J , . Ibrutinib monotherapy in relapsed\/refractory follicular lymphoma (FL): Preliminary results of a phase 2 consortium trial. Paper presented at the 56th annual meeting of the American Society for Hematology; December 2014; San Francisco, CA.","DOI":"10.1182\/blood.V124.21.800.800"},{"key":"2016123117301574000_109.3.djw255.45","doi-asserted-by":"crossref","unstructured":"Dreyling M Morschhauser F Bron D , . Preliminary results of a phase II study of single agent bay 80-6946, a novel PI3K inhibitor, in patients with relapsed\/refractory, indolent or aggressive lymphoma. Paper presented at the 55th annual meeting of the American Society for Hematology; December 2013; New Orleans, LA.","DOI":"10.1182\/blood.V122.21.87.87"},{"key":"2016123117301574000_109.3.djw255.46","doi-asserted-by":"crossref","unstructured":"Flinn I Oki Y Patel M , . A phase 1 evaluation of duvelisib (IPI-145), a PI3K-\u03b4,\u03b3 inhibitor, in patients with relapsed\/refractory NHL. Paper presented at the 56th Annual Meeting of the American Society of Hematology; December 2014; San Francisco, CA.","DOI":"10.1182\/blood.V124.21.802.802"},{"key":"2016123117301574000_109.3.djw255.47","doi-asserted-by":"crossref","unstructured":"Burris HA Patel MR Fenske TS , . Clinical activity and safety profile of TGR-1202, a novel once-daily PI3K-delta inhibitor, in patients with CLL and B-cell lymphoma. Paper presented at the 57th Annual Meeting of the American Society of Hematology; December 2015; Orlando, FL.","DOI":"10.1200\/jco.2015.33.15_suppl.7069"},{"key":"2016123117301574000_109.3.djw255.48","unstructured":"Gilead Sciences Inc. Idelalisib Urgent Safety Letter. 2016."}],"container-title":["Journal of the National Cancer Institute"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T15:48:42Z","timestamp":1601135322000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djw255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,31]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,12,31]]},"published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1093\/jnci\/djw255"],"URL":"https:\/\/doi.org\/10.1093\/jnci\/djw255","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,31]]}}}